ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Ankylosing spondylitis (AS)"

  • Abstract Number: 2348 • 2013 ACR/ARHP Annual Meeting

    Long Term Safety Of Intravenous Golimumab and Comparisons With Subcutaneous Golimumab In Rheumatologic Conditions:  Results From The 120-Day Safety Report Of a Phase 3 Trial Of Intravenous Golimumab

    Rene Westhovens1, Clifton O. Bingham III2, Michael E. Weinblatt3, Roy Fleischmann4, Edward C. Keystone5, Elizabeth C. Hsia6, Benjamin Hsu6, Lilianne Kim6, Surekha Mudivarthy6, Michael Mack7, Neil Goldstein6, Jürgen Braun8, Arthur Kavanaugh9, Alan M. Mendelsohn10 and Jonathan Kay11, 1Rheumatology, University Hospital KU Leuven, Leuven, Belgium, 2Rheumatology, Johns Hopkins University, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4University of Texas Southwestern Medical Center, Dallas, TX, 5Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 6Janssen Research & Development, LLC., Spring House, PA, 7Biostatistics, Janssen Research & Development, LLC., Spring House, PA, 8PsAID taskforce, EULAR, Zurich, Switzerland, 9University of California San Diego, San Diego, CA, 10Immunology, Janssen Research & Development, LLC., Spring House, PA, 11UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA

    Background/Purpose:   To describe safety profile of IV GLM in RA from the Ph3 GLM IV program. AE rates of interest are indirectly compared to…
  • Abstract Number: 1548 • 2013 ACR/ARHP Annual Meeting

    Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis

    Nisha Nigil Haroon1, Jeevitha Srighanthan2, Nayef AL Ghanim3, Robert D. Inman4,5,6,7,8,9 and Angela Cheung10, 1Medicine, University of Toronto, Toronto, ON, Canada, 2Osteoporosis Program, University of Toronto, Ontario, ON, Canada, 3Rheumatology, University of Toronto, Toronto, ON, Canada, 4Toronto Western Hospital, Toronto, ON, Canada, 5Rheumatology, Toronto Western Research Institute. University of Toronto, Toronto, ON, Canada, 6University of Toronto, Toronto, ON, Canada, 7Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 8U of Toronto, Toronto, ON, Canada, 9Dept of Medicine/Rheumatology, The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 10Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Patients with ankylosing spondylitis (AS) are susceptible to osteoporosis (OP) and have high fracture risk. Currently, no specific strategies are established to treat OP…
  • Abstract Number: 1417 • 2013 ACR/ARHP Annual Meeting

    Lack Of Correlation Between Golimumab Exposure and Selected Safety Events Following Intravenous Or Subcutaneous Administration In An Integrated Analysis Of Phase 3 Data Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Or Ankylosing Spondylitis

    Jocelyn H. Leu1, Anna Beutler1, Alan M. Mendelsohn2, Sam Liao3, Hugh M. Davis1, Honghui Zhou1 and Zhenhua Xu1, 1Janssen Research & Development, LLC., Spring House, PA, 2Immunology, Janssen Research & Development, LLC., Spring House, PA, 3PharMax Research, Inc., Newport Beach, CA

    Background/Purpose: For anti-TNFα agents, infections and malignancies are key safety concerns.  It is unknown whether safety events are driven by peak (Cmax), trough (Cmin), average…
  • Abstract Number: 385 • 2013 ACR/ARHP Annual Meeting

    Systemic Inflammation In Patients With Inflammatory Joint Disease Does Not Influence Statin Dose Needed To Obtain Low Density Lipoprotein Cholesterol Goal In Cardiovascular Prevention

    Silvia Rollefstad1, Eirik Ikdahl2, Tore K. Kvien3,4, Terje R. Pedersen4,5, Ingar Holme6 and Anne G. Semb2, 1Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Faculty of Medicine, University of Oslo, Oslo, Norway, 5Centre of Preventive Medicine, Oslo University Hospital-Ullevaal, Oslo, Norway, 6Department of biostatistics, epidemiology and health economics, Oslo University Hospital-Ullevaal, Oslo, Norway

    Background/Purpose: There is a lipid paradox in rheumatoid arthritis (RA): despite low lipids influenced by systemic inflammation, there is an increased risk of cardiovascular (CV)…
  • Abstract Number: 2491 • 2013 ACR/ARHP Annual Meeting

    Serum Levels Of Novel Noggin- and Sclerostin-Immune Complexes Are Elevated In Ankylosing Spondylitis

    Florence W. Tsui1, Hing Wo Tsui2 and Robert D. Inman3, 1Genetics and Development / Immunology, Toronto Western Research Institute UHN and University of Toronto, Toronto, ON, Canada, 2Genetics and Development, Toronto Western Research Institute UHN, Toronto, ON, Canada, 3Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Unravelling the basis of joint inflammation and ankylosis represents a major challenge in ankylosing spondylitis (AS) research. As noggin (NOG) and sclerostin (SOST) have…
  • Abstract Number: 2160 • 2013 ACR/ARHP Annual Meeting

    The Journey to Diagnosis in As/Axial Spondyloarthritis – the Psychological Impact of Delay

    Jane Martindale1,2 and Lynne Goodacre2, 1Physiotherapy, Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom, 2Faculty of Health and Medicine, Lancaster University, Lancaster, United Kingdom

    Background/Purpose: It is not uncommon for 8 to 11 years to pass between symptoms onset and definitive diagnosis of AS/axial SpA (Gran 1997, Feldtkeller, 2003).…
  • Abstract Number: 1552 • 2013 ACR/ARHP Annual Meeting

    Effective Prevention Of New Osteitis On Magnetic Resonance Imaging In Patients With Early Axial Spondyloarthritis During 3 Years Of Continous Treatment With Etanercept – Data Of The Esther Trial

    In-Ho Song1, Kay-Geert A. Hermann2, Hildrun Haibel3, Christian Althoff4, Denis Poddubnyy3, Joachim Listing5, Anja Weiss6, Ekkehard Lange7, Bruce Freundlich8, Martin Rudwaleit9 and Joachim Sieper10, 1Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, 2Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 3Charité Universitätsmedizin Berlin, Berlin, Germany, 4Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 5German Rheumatism Research Center, Berlin, Germany, 6German Rheumatism Research Centre, Berlin, Germany, 7BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, 8University of Pennsylvania, Philadelphia, PA, 9Endokrinologikum, Berlin, Germany, 10Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin, Berlin, Germany

    Background/Purpose:   In patients with early axial spondyloarthritis (SpA) with a disease duration of
  • Abstract Number: 1367 • 2013 ACR/ARHP Annual Meeting

    Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry

    ŽIga Rotar1 and Matija Tomsic2, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia

    Background/Purpose: Reactivation of latent tuberculosis infection (LTBI) is of concern in patients treated with TNFi. Conversely, TB chemoprophylaxis (CP) is time consuming, delays the initiation…
  • Abstract Number: 332 • 2013 ACR/ARHP Annual Meeting

    Risk Of Cardiovascular Disease Among Patients With Psoriatic Arthritis Compared To Ankylosing Spondylitis (retrospective cohort study)

    Zohair Abbas1 and Marina N. Magrey2, 1Rheumatology, Case Western Reserve University at Metrohealth Medical Center, Cleveland, OH, 2Department of Medicine, Division of Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH

    Background/Purpose: Both patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are at increased risk of cardiovascular disease (CVD). This increased risk is in part…
  • Abstract Number: 2451 • 2013 ACR/ARHP Annual Meeting

    Work Instability Scores In Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Are Equal and Higher Than In Psoriatic Arthritis

    Sherry Rohekar1, Robert D. Inman2 and Dafna D. Gladman3, 1Rheumatology, St. Joseph's Hospital, London, ON, Canada, 2Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Clinical subsets of spondyloarthitis (SpA), such as ankylosing spondylitis (AS) and psoriatic arthritis (PsA) may be associated with significant impact on work performance and…
  • Abstract Number: 2105 • 2013 ACR/ARHP Annual Meeting

    Differences In Spinal Mobility Measures In Relation To Disease Duration and Between Subgroups With Axial Spondyloarthritis

    Elisabeth.A Mogard1, Elisabet Lindqvist2, Stefan Bergman3,4 and Ann B. I. Bremander4, 1Department of Clinical Sciences, Section of Rheumatology and Skåne University Hospital, Lund University, Lund, Sweden, 2Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund University, Lund, Sweden, 3Spenshult Research and Development Center, Halmstad, Sweden, 4Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden

    Background/Purpose: Spinal mobility is a core domain for research and clinical practice in Ankylosing Spondylitis (AS) but less studied in undifferentiated SpA (USpA). Our objective…
  • Abstract Number: 1521 • 2013 ACR/ARHP Annual Meeting

    Latent Tuberculosis Screening and Treatment In Ankylosing Spondylitis Patients Eligible For Anti-TNF Therapy In Endemic Area

    Renata Miossi1, Karina Rossi Bonfiglioli1, Carla G.S. Saad2, Ana Cristina Ribeiro1, Julio C. B. Moraes2 and Eloisa Bonfá1, 1Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Anti-TNF agents have emerged as an important treatment for rheumatic diseases, particularly for ankylosing spondylitis (AS). Screening and treatment of latent tuberculosis infection (LTBI)…
  • Abstract Number: 1222 • 2013 ACR/ARHP Annual Meeting

    Analysis Of Corelation Of Bone Mineral Density Of Spine With Other Sites In Ankylosing Spondylitis As Compared To Rheumatoid Arthritis and Control Populations

    Janie Bruce1 and Vikas Majithia2,3, 1Div of Rheumatology, University of Mississippi School of Medicine, Jackson, MS, 2Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, 3G.V. "Sonny" Montogomery VA Medical Center, Jackson, MS

    Background/Purpose: Bone mineral density (BMD) at the 3 central sites usually correlates with each other but the effect of disease states on this correlation is…
  • Abstract Number: 184 • 2013 ACR/ARHP Annual Meeting

    Are Physician Gender, Age and Clinical Experience Associated With Discrepancy In Global Disease Score In Rheumatoid Arthritis, Ankylosing  Spondylitis and Psoriatic Arthritis? Data From The Nationwide Danbio Registry

    Cecilie Lindstrom Egholm1, Niels Steen Krogh2, Lene Dreyer3, Torkell Ellingsen4, Bente Glintborg5, Marcin Kowalski6, Tove Lorenzen7, Ole Rintek Madsen8, Henrik Nordin9,10, Claus Rasmussen11 and Merete L. Hetland12, 1Regional Research Unit, Region Zealand, Roskilde, Denmark, 2ZiteLab ApS, Copenhagen, Denmark, 3Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, 4Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, 5Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, 6Aalborg University Hospital, Aalborg, Denmark, 7Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, 8Department of Rheumatology, Copenhagen University Hospital in Gentofte, Copenhagen, Denmark, 9Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, 10DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, 11Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, 12Copenhagen University Hospital Glostrup, Copenhagen, Denmark

    Background/Purpose: A global estimate on a 100 mm Visual Analogue Scale (VAS) assessed by patients (PATGL) and physicians (DOCGL) is commonly used to measure disease…
  • Abstract Number: 2885 • 2013 ACR/ARHP Annual Meeting

    Erosions and Sclerosis, But Not Squaring, Predict The Development Of New Syndesmophytes: A 12-Year Longitudinal Analysis (OASIS)

    Sofia Ramiro1, A.M. van Tubergen2, Désirée van der Heijde3, Carmen Stolwijk4, Maxime Dougados5, Filip Van den Bosch6 and Robert Landewé7, 1Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 5Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 6Ghent University Hospital, Ghent, Belgium, 7Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands

    Background/Purpose: Erosions, sclerosis and squaring are included in the modified Stoke Ankylosing Spondylitis (AS) Spine Score (mSASSS). However, their value in predicting the development of…
  • « Previous Page
  • 1
  • …
  • 58
  • 59
  • 60
  • 61
  • 62
  • …
  • 67
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology